Oncology Associates of Oregon, P.C.

Clinical research site in Eugene, Oregon · 520 COUNTRY CLUB, EUGENE, OR 97401-6036 · (541) 683-5001

Part of Oncology Associates of Oregon

As of July 2026, 34 paid clinical trials are recruiting at Oncology Associates of Oregon, P.C. in Eugene, Oregon. Active studies at this site cover conditions such as Advanced/Metastatic Non-Small Cell Lung Cancer, Advanced/Metastatic Urothelial Cancer and Breast Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Oncology Associates of Oregon, P.C. (34)

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

for Urothelial Cancer

74 locations incl. Fayetteville

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07421700·Phase 1, Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

for Non-small Cell Lung Cancer (NSCLC)

37 locations incl. Daphne

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07361497·Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

for Intestinal Neoplasms

166 locations incl. Chandler

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07222800·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

for Advanced/Metastatic Non-Small Cell Lung Cancer

27 locations incl. Fayetteville

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07227298·Phase 1, Phase 2·Recruiting·Listed Nov 2025

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

for Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

34 locations incl. Phoenix

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07221149·Phase 2, Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

for Ovarian Neoplasms

88 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07213804·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

for Breast Neoplasms

116 locations incl. Anchorage

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

for Ovarian Cancer

38 locations incl. Anchorage

Sponsor: Incyte Corporation

Sex: Female·Age: 18+

Code: NCT07214779·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

for Non-small Cell Carcinoma

133 locations incl. Alabaster

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT07144280·Phase 3·Recruiting·Listed Aug 2025

Apply to this trial

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

for Early Breast Cancer

85 locations incl. Birmingham

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18 - 100

Code: NCT05827081·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

for Follicular Lymphoma (FL)

32 locations incl. Fresno

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT06191744·Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

88 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

for Breast Cancer

134 locations incl. Daphne

Sponsor: Pfizer

Sex: All·Age: 18+

Code: NCT06966453·Phase 1, Phase 2·Recruiting·Listed May 2025

Apply to this trial

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

for NSCLC (Non-small Cell Lung Cancer)

43 locations incl. Birmingham

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06881784·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

for B-Cell Non-Hodgkins Lymphoma

33 locations incl. Anchorage

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06806033·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

for Endometrial Cancer

43 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: Female·Age: 18+

Code: NCT06952504·Phase 3·Recruiting·Listed May 2025

Apply to this trial

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

for Large B-cell Lymphoma

60 locations incl. Gilbert

Sponsor: Allogene Therapeutics

Sex: All·Age: 18+

Code: NCT06500273·Phase 2·Recruiting·Listed Jul 2024

Apply to this trial

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

for High Grade Epithelial Ovarian Cancer

37 locations incl. Phoenix

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT05579366·Phase 1, Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

for Small Cell Lung Cancer

27 locations incl. Daphne

Sponsor: Puma Biotechnology, Inc.

Sex: All·Age: 18+

Code: NCT06095505·Phase 2·Recruiting·Listed Oct 2023

Apply to this trial

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

for Epithelial Ovarian Cancer

65 locations incl. Birmingham

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT06890338·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

for Solid Cancer

26 locations incl. Anchorage

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06161025·Phase 2, Phase 3·Recruiting·Listed Dec 2023

Apply to this trial

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

for Non Small Cell Lung Cancer

46 locations incl. Dothan

Sponsor: OncoC4, Inc.

Sex: All·Age: 18+

Code: NCT05671510·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

for Leukemia, Myeloid, Acute

30 locations incl. Newport Beach

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 12+

Code: NCT04988555·Phase 1, Phase 2·Recruiting·Listed Aug 2021

Apply to this trial

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

for Solid Tumors

15 locations incl. Bellflower

Sponsor: Mirati Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT07415031·Phase 2·Recruiting·Listed Feb 2026

Apply to this trial

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

for Relapsed/Refractory Acute Myeloid Leukemia

18 locations incl. Duarte

Sponsor: SystImmune Inc.

Sex: All·Age: 18+

Code: NCT06714591·Phase 1·Recruiting·Listed Dec 2024

Apply to this trial

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

22 locations incl. Birmingham

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06343402·Phase 1·Recruiting·Listed Apr 2024

Apply to this trial

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

for Polycythemia Vera

14 locations incl. Birmingham

Sponsor: Italfarmaco

Sex: All·Age: 18+

Code: NCT06093672·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

for Endometrial Cancer

18 locations incl. La Jolla

Sponsor: Faeth Therapeutics

Sex: Female·Age: 18+

Code: NCT06463028·Phase 2·Recruiting·Listed Jun 2024

Apply to this trial

A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

for Higher-risk Myelodysplastic Syndromes

14 locations incl. Los Angeles

Sponsor: Akeso

Sex: All·Age: 18+

Code: NCT06196203·Phase 2·Recruiting·Listed Jan 2024

Apply to this trial

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

for Endometrial Cancer

19 locations incl. Vallejo

Sponsor: Kartos Therapeutics, Inc.

Sex: Female·Age: 18+

Code: NCT05797831·Phase 2, Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)

for Colon Cancer

14 locations incl. Denver

Sponsor: SCRI Development Innovations, LLC

Sex: All·Age: 18+

Code: NCT07011576·Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

for Multiple Myeloma

16 locations incl. Tucson

Sponsor: SCRI Development Innovations, LLC

Sex: All·Age: 18+

Code: NCT05972135·Phase 2·Recruiting·Listed Aug 2023

Apply to this trial

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

for Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)

9 locations incl. Denver

Sponsor: Institut de Recherches Internationales Servier

Sex: All·Age: 18+

Code: NCT06465953·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

for Limited-stage Small Cell Lung Cancer (LS-SCLC)

29 locations incl. Goodyear

Sponsor: Shanghai Junshi Bioscience Co., Ltd.

Sex: All·Age: 18+

Code: NCT06095583·Phase 3·Recruiting·Listed Oct 2023

Apply to this trial

More research sites in Eugene

Willamette Valley Cancer Institute and Research Center (11 trials)
University of Oregon (10 trials)
Oncology Associates of Oregon (8 trials)
Verum Research, LLC (7 trials)
Willamette Valley Cancer Institute (5 trials)
Prevention Science Institute (4 trials)
Chestnut Health Systems (3 trials)
Oncology Associates Of Oregon, Pc (3 trials)
Verum Research LLC (3 trials)
Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) (3 trials)

Explore more

Paid clinical trials in Eugene, OR · Oregon clinical trials